Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year ... investing in growth opportunities -- its growth days are by no means over. Currently, the stock trades at ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple of ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.

extending its streak of annual dividend growth to 15 consecutive years. The stock supports a dividend yield of 6.5%, as of March 6. Overall, PFE ranks 3rd on our list of best cheap dividend stocks ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...